(ELAN) Elanco Animal Health - Ratings and Ratios

Elanco Animal Health Incorporated, a global leader in animal health, specializes in the innovation, development, manufacturing, and marketing of products for pets and farm animals. The company provides a diverse portfolio of pet health solutions, including parasiticides, vaccines, and therapeutics designed to protect pets from fleas, ticks, and internal parasites. Key products include the Seresto, K-9 Advantage, and Advantix brands for flea and tick prevention, as well as prescription and over-the-counter treatments under the Credelio and Interceptor Plus brands. Its vaccine portfolio offers comprehensive protection against major pet health risks, while its therapeutics address pain, otitis, cardiovascular issues, dermatology, and osteoarthritis in dogs and cats, notably under the Galliprant trademark.

For farm animals, Elanco provides solutions to enhance health and productivity in livestock such as cattle, swine, and poultry. The company offers medicated feed additives like Rumensin, injectable antibiotics such as Baytril, and vaccines and enzymes to improve animal wellbeing. Its poultry health products, including Maxiban and Monteban, focus on preventing and controlling intestinal diseases. Additional offerings for pets include Atopica for skin allergies and Milbemax for parasitic infections, while farm animal solutions extend to AviPro and Denagard for poultry and cattle health.

Elanco distributes its products through third-party distributors, independent retailers, and direct sales to veterinarians and farm producers. Founded in 1954 and headquartered in Greenfield, Indiana, the company has established itself as a key player in the animal health sector, balancing innovation with practical solutions for both companion and livestock animals.

Ticker Symbol: ELAN Exchange: NYSE Type: common stock Country Origin: United States GICS Sub Industry: Pharmaceuticals

Based on the provided technical and fundamental data, here is a 3-month forecast:

Technical Outlook: The stock is currently trading below its SMA 20 and SMA 50, indicating bearish momentum. The SMA 200 at 12.43 suggests a potential resistance level. ATR of 0.54 signals moderate volatility, with support levels likely near the SMA 20 at 9.19. A breakdown below this level could test lower supports, while a reversal above SMA 50 at 10.19 may signal a bullish trend.

Fundamental Outlook: With a market cap of $4.19 billion and a P/S ratio of 0.94, the stock appears undervalued relative to its peers. A forward P/E of 10.02 indicates expectations of earnings growth. The RoE of 5.54% reflects modest profitability, but the companys diverse product portfolio and market position suggest potential for stabilization and recovery in the medium term.